GCL
FOLD

Glazer Capital LLC’s Amicus Therapeutics FOLD Stock Holding History

Glazer Capital LLC’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,722,749
Closed -$184M – 568
2026
Q1 		$184M Buy
12,722,749
+11,118,961
+693% +$159M 3.9% 5
2025
Q4 		$22.8M Buy
+1,603,788
New +$15.8M 0.6% 30

Other funds holding FOLD

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Glazer Capital LLC's FOLD Position: Q2 2026 in Review

Glazer Capital LLC sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 12,722,749 shares — an estimated $184M sold.

Glazer Capital LLC first reported a position in FOLD in Q4 2025 and held it in 2 quarters. The position peaked at $184M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • Glazer Capital LLC reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Glazer Capital LLC sold 12,722,749 Amicus Therapeutics shares in Q2 2026, an estimated $184M.
  • Glazer Capital LLC first reported a position in Amicus Therapeutics in Q4 2025 and held it in 2 quarters.
  • Glazer Capital LLC's Amicus Therapeutics position peaked at $184M in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Glazer Capital LLC's 13F filing for Q2 2026, filed 17 Aug 2026.